Mylan’s stock price has jumped more than 70% since Bresch stepped in as CEO at the generic-drug maker in 2012. She continues to break new ground at the company, with $6.8 billion in revenue; a $1.6 billion acquisition of India pharma business Agila Specialties is pending, and Mylan entered the diagnostics market for the first time by winning rights to distribute a test used in the treatment of HIV/AIDS.